Foresite Capital Fund V, L.P.'s Form 4 filing
Latigo Biotherapeutics, Inc. (LTGO) · filed Aug 10, 2026
- Accession no.
- 0001104659-26-093580
- Filed
- Aug 10, 2026, 8:21 PM ET
- Trade date
- Aug 10, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 7 derivative transactions. Open-market purchases total $2.52M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Foresite Capital Fund V, L.P.CIK 0001792204 | 10% Owner |
| Foresite Capital Opportunity Fund V, L.P.CIK 0001792205 | 10% Owner |
| Foresite Capital Management V, LLCCIK 0001792206 | 10% Owner |
| Foresite Capital Opportunity Management V, LLCCIK 0001792207 | 10% Owner |
| Foresite Capital Fund VI LPCIK 0001932516 | 10% Owner |
| Foresite Capital Management VI LLCCIK 0002013341 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | CConversionAcquired | +3,117,664 | $0.00 | $0 | 3,117,664 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +445,320 | $0.00 | $0 | 3,562,984 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +1,125,823 | $0.00 | $0 | 1,125,823 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +742,201 | $0.00 | $0 | 1,868,024 | Indirect | |
| Aug 10, 2026 | Common Stock | PPurchaseAcquired | +140,000 | $18.00 | +$2,520,000 | 2,008,024 | Indirect | Duplicate filing |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +195,776 | –F5 | – | 2,203,800 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +3,117,664 | $0.00 | $0 | 3,117,664 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionAcquired | +296,880 | $0.00 | $0 | 3,414,544 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Common Stock | CConversionDisposed | −3,117,664 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −445,320 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −1,125,823 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −742,201 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −3,117,664 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −296,880 | $0.00 | $0 | 0 | Indirect | |
| Aug 10, 2026 | Common Stock | CConversionDisposed | −195,776 | –F5 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F5
Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of June 17, 2027. The principal amount of the convertible note together with any accrued but unpaid interest automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a conversion price equal to the initial public offering price of the Issuer's common stock.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.